Yeda Research and Develpment & Co. Ltd

Harvard College

Leland Stanford Junior University

Agence Nationale De Valorisation De La Recherche (anvar)

Yeda Research and Development Ltd.

Veda Research and Development Co., Ltd.

Michael Sela

Ruth Arnon

Dvora Teitelbaum

Eliezer Konfino

Yosef Yarden

Bilha Schechter

Ruth Maron

Rina Aharoni

Irun R Cohen

Michal Eisenbach-Schwartz

Jack L Strominger

Masha Fridkis-Hareli

Jonathan Kipnis

Eti Yoles

Tsipi Ben-Kasus

Esther Hurvitz

Jean Choay

Louis A Chedid

Pierre Lefrancier

Edgar Lederer

Francoise Marguerite Audibert

Edna Mozes

Monique Parant

Adrian Gilbert

Milka Linenberg

Rivka Riven-Kreitmann

Georg Mahlknecht

Nelson J Chao

Paul G Schlegel

Samario Chaitchik

Ron Levy

Chaim O Jacob

Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

Aptamers, multimeric aptamers and uses thereof

A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

Antibody combinations and use of same for treating cancer

An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

Combinations of anti ErbB antibodies for the treatment of cancer

The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.

Copolymer-1 improvements in compositions of copolymers

A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity.

Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising same

Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies

The present invention is directed to polypeptides containing at least three amino acids randomly joined in a linear array; wherein at least one of the three amino acids is an aromatic amino acid, at least one of the three amino acids is a charged amino acid and at least one amino acid is an aliphatic amino acid. In a preferred embodiment the polypeptide contains three or four of the following amino acids: tyrosine, alanine, glutamic acid or lysine. According to the present invention, the present polypeptides bind to antigen presenting cells, purified human lymphocyte antigens (HLA) and/or Copolymer 1-specific T cells. Moreover, according to the present invention, these polypeptides can be formulated into pharmaceutical compositions for treating autoimmune disease. The present invention further contemplates methods of treating an autoimmune disease in a mammal by administering a pharmaceutically effective amount of any one of the present polypeptides to the mammal.

Treatment of autoimmune conditions with Copolymer 1 and related Copolymers

Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.

Use of copolymer 1 and related peptides and polypeptides and T cells treated herewith for neuroprotective glaucoma therapy

The present invention provides heteropolymer compositions and peptide compositions, and methods of making and using therapeutic compositions comprising amino acid heteropolymers for treatment of a subject for an autoimmune or an inflammatory disease, the heteropolymer compositions made by solid state synthesis. The invention also provides kits for assaying binding of a composition to a water-soluble MHC protein.

Treatment of autoimmune conditions with copolymer 1 and related copolymers

Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy

Growing community of inventors

Rehovot, Israel

Michael Sela